Everest Medicines, a Shanghai in-licensing company, has begun dosing patients in a China Phase III trial of a treatment for autoimmune renal disease. Everest acquired China rights to Nefecon from Calliditas Therapeutics of Stockholm . Calliditas has completed a Phase III trial of the candidate in patients with IgA nephropathy (IgAN), a rare renal disease for which there are no treatments. Everest will enroll some China patients in the 160-person global Part B Phase III trial, which is being conducted to validate the biomarker, proteinuria. More details.... Share this with colleagues: // //